 WATERTOWN, Mass., July 29, 2020 GLOBE NEWSWIRE -- EyePoint Pharmaceuticals, Inc. NASDAQ: EYPT, a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its second quarter 2020 on Wednesday, August 5, 2020. Management will host a conference call to review the results at 8:30 AM ET on the same day. The conference call may be accessed by dialing 877 312-7507 from the U.S. and Canada or 631 813-4828 from international locations. The conference ID is 5816799. A live webcast will be available on the Investor Relations section of the corporate website at A webcast replay will also be available on the corporate website at the conclusion of the call.About EyePoint PharmaceuticalsEyePoint Pharmaceuticals, Inc. is a pharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company currently has two commercial products: DEXYCU, the first approved intraocular product for the treatment of postoperative inflammation, and YUTIQ, a three-year treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The Companys pipeline leverages its proprietary bioerodible Durasert technology for extended intraocular drug delivery including EYP-1901, a potential single dose, six month VEGF inhibitor initially targeting wet age-related macular degeneration. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts with offices in Basking Ridge, New Jersey. To learn more about the Company, please visit and connect on Twitter and LinkedIn.ContactsInvestors: Argot Partners Sam Martin or Joe Rayne 212-600-1902 Media: Thomas Gibson 201-476-0322 